Overview

Investigator Initiated Phase 1 Study of TBI-1201

Status:
Completed

Trial end date:
2021-03-01

Target enrollment:

Participant gender:

Summary

Following pre-treatment with cyclophosphamide and/or fludarabine, MAGE-A4-specific TCR gene transduced T lymphocytes are transferred to the patients with MAGE-A4-expressing solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Mie University

Collaborators:

Fiverings Co., Ltd.
Shionogi
Statcom Co. Ltd.
Takara Bio Inc.

Treatments:

Cyclophosphamide
Fludarabine
Fludarabine phosphate